Minocycline adjunctive therapy may be beneficial in schizophrenia, with documented improvement in cognitive (Levkovitz et al., 2010; Zhang et al., 2019), positive (Zhang et al., 2019), and negative (Levkovitz et al., 2010; Liu et al., 2014; Palleja et al., 2018) symptoms and reduction of inflammatory cytokines IL-1β and IL-6 (Palleja et al., 2018; Zhang et al., 2019). The gene discussed is IL6; the disease is schizophrenia.